- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for 2017
The Center for Biosimilars recaps the most-read articles of 2017.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the most-read biosimilars articles for the year of 2017.
Number 5: In January, The Center for Biosimilars® provided a look at the marketplace for prospective biosimilars referencing Humira, Enbrel, and Remicade.
Number 4: In December, the FDA approved Mylan and Biocon’s trastuzumab biosimilar, Ogivri, referenced on Herceptin.
Number 3: In January, Pfizer announced that CMS would reimburse for its biosimilar infliximab.
Number 2: In September, the FDA released a heavily redacted Form 483, noting observations that it made when inspecting Celltrion’s manufacturing facility earlier in 2017.
Number 1: In October, the FDA issued a Complete Response Letter for Mylan and Biocon’s pegfilgrastim biosimilar, referenced on Neulasta.
To read all of these articles and more, visit centerforbiosimilars.com.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
